Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001402
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers
Status:
COMPLETED
Status Verified Date:
1999-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The human heart is divided into four chambers One of the four chambers the left ventricle is the chamber mainly responsible for pumping blood out of the heart into the circulation Diseases of the heart like congestive heart failure CHF can cause the left ventricle to function improperly
Medications called beta-blockers appear to reverse the abnormalities in the left ventricle and frequently improve the function of the left ventricle in patients with different kinds of heart disease How beta-blockers improve left ventricle function is unknown
One possible reason for improved function of the left ventricle with beta-blockers is improved blood flow to the heart muscle When a region of the heart is active it uses more fuel in the form of oxygen and sugar glucose As heart activity increases blood flow to and from the area of activity increases also Knowing these facts researchers can use radioactive sugar glucose and positron emission tomography PET scans to observe what areas of the heart are receiving more blood flow
In this study researchers plan to measure glucose use in heart muscle and blood flow to the heart muscle in patients with CHF taking beta-blockers
Medications called beta-blockers appear to reverse the abnormalities in the left ventricle and frequently improve the function of the left ventricle in patients with different kinds of heart disease How beta-blockers improve left ventricle function is unknown
One possible reason for improved function of the left ventricle with beta-blockers is improved blood flow to the heart muscle When a region of the heart is active it uses more fuel in the form of oxygen and sugar glucose As heart activity increases blood flow to and from the area of activity increases also Knowing these facts researchers can use radioactive sugar glucose and positron emission tomography PET scans to observe what areas of the heart are receiving more blood flow
In this study researchers plan to measure glucose use in heart muscle and blood flow to the heart muscle in patients with CHF taking beta-blockers
Detailed Description:
Deterioration in left ventricular function which is characteristic in patients with congestive heart failure appears to be a multifactorial process Beta-blockers appear to reverse the deterioration and frequently improve left ventricular function in patients with both ischemic and non-ischemic cardiomyopathies The mechanism by which beta-blockers improve ejection fraction is not known Although it is well established that regional flow function and metabolism may improve after coronary revascularization whether beta-blocker therapy will have similar salutary results in patients with congestive heart failure is unknown The aim of this study is to 1 quantitate regional glucose uptake and regional blood flow before and after chronic beta-blocker administration to patients with congestive heart failure using positron emission tomography 2 determine if alteration in either regional glucose or lipid uptake or regional blood flow correlate with improvement in wall motion and global left ventricular function and 3 determine if ischemic and nonischemic myocardium differ in blood flow or metabolism
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 94-H-0054 | None | None | None |